Wegovy major change from April 14 for certain people using jab to lose weight

Wegovy major change from April 14 for certain people using jab to lose weightThe Medicines and Healthcare products Regulatory Agency has made an announcement affecting people using the weight loss jabCommentsNewsElaine Blackburne Network Content Editor12:02, 14 Apr 2026Updated 12:04, 14 Apr 2026View 3 ImagesPreviously people had to have three injections on the same day(Image: Getty)Thousands of people could see a change to their weight loss jab after a new ruling by a health body. It is estimated more than 1.6m people in the UK use weight loss drugs such as Wegovy and Mounjaro.‌Now the Medicines and Healthcare products Regulatory Agency (MHRA) has approved a change in the way the drug is administered. Starting from Tuesday, Apri 14, people will be able to use a new single-dose 7.2mg semaglutide (Wegovy) pen to treat adult patients with obesity, who have a Body Mass Index (BMI) of 30kg/m² or higher.‌The approval will support adult patients with obesity by providing the option of a single-dose injection to receive the maximum weekly dose for weight loss and weight management. The 7.2mg dose is administered via one injection.‌View 3 ImagesAn estimated 1.6 million adults in England, Scotland and Wales are thought to have used the drug(Image: Getty)However the change does not apply to overweight patients with a BMI of less than 30kg/m² using Wegovy for weight management. It also excludes patients using Wegovy to lower their risk of serious heart problems.‌This decision follows the January 2026 authorisation of the 7.2mg maximum weekly dose. This required three 2.4mg doses administered on the same day using the standard 2.4mg pen.When patients start using Wegovy, the starting dose is 0.25mg per week, which will be gradually increased every four weeks as required and prescribed by the appropriate healthcare professional. The maximum dose is 7.2mg per week.View 3 ImagesPeople have had good weight loss with the help of the jabs(Image: Getty)Article continues belowThe MHRA ha...